Unknown

Dataset Information

0

CXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy: a pilot study.


ABSTRACT:

Background and aims

There is lack of a practical biomarker to predict sustained virological response (SVR) in chronic hepatitis B (CHB) patients undergoing peginterferon alfa-2a (PEG-IFN). The aim of this pilot study was to identify immunological features associated with SVR.

Methods

Consecutive 74 CHB patients receiving 24 weeks (for hepatitis B e antigen (HBeAg)-positive) or 48 weeks (for HBeAg-negative) PEG-IFN, were prospectively enrolled. Serum HBV viral loads, hepatitis B surface antigen (HBsAg), CXCL9, IFN-?-inducible protein 10 (IP-10), interferon-gamma (IFN-?) and transforming growth factor beta (TGF-?) were measured at baseline and week 12. SVR was defined as HBeAg seroconversion combined with viral load <2000 IU/mL in HBeAg-positive (n=36), and viral load <2000 IU/mL in HBeAg-negative patients (n=38) at 48 weeks after the end of treatment.

Results

Nineteen patients (25.7%), 7 in HBeAg-positive and 12 in HBeAg-negative, achieved SVR. There were significant declines of HBV DNA, HBsAg, IP-10 and IFN-? levels at week 12. In multivariate analysis, pre-treatment CXCL9 >80 pg/mL, HBV DNA <2.5 x 10(7) IU/mL and on-treatment HBV viral load, HBsAg decline >10% at week 12 were predictors of SVR. The performance of CXCL9 in predicting SVR was good in patients with HBV DNA <2.5 x 10(7) IU/mL, particularly in HBeAg-negative CHB cases (positive predictive value, PPV= 64.3%).

Conclusions

Pre-treatment CXCL9 level has the potential to select CHB patients who can respond to PEG-IFN, especially in HBeAg-negative patients with low viral loads.

SUBMITTER: Lee IC 

PROVIDER: S-EPMC3790882 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature

altmetric image

Publications

CXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy: a pilot study.

Lee I-Cheng IC   Huang Yi-Hsiang YH   Su Chien-Wei CW   Wang Yuan-Jen YJ   Huo Teh-Ia TI   Lee Kuei-Chuan KC   Lin Han-Chieh HC  

PloS one 20131004 10


<h4>Background and aims</h4>There is lack of a practical biomarker to predict sustained virological response (SVR) in chronic hepatitis B (CHB) patients undergoing peginterferon alfa-2a (PEG-IFN). The aim of this pilot study was to identify immunological features associated with SVR.<h4>Methods</h4>Consecutive 74 CHB patients receiving 24 weeks (for hepatitis B e antigen (HBeAg)-positive) or 48 weeks (for HBeAg-negative) PEG-IFN, were prospectively enrolled. Serum HBV viral loads, hepatitis B su  ...[more]

Similar Datasets

| S-EPMC4554122 | biostudies-literature
| S-EPMC4798721 | biostudies-literature
| S-EPMC3856983 | biostudies-literature
| S-EPMC4521757 | biostudies-literature
| S-EPMC1860092 | biostudies-literature
| S-EPMC2716864 | biostudies-other
| S-EPMC6541521 | biostudies-literature
| S-EPMC6465180 | biostudies-literature
| S-EPMC5510621 | biostudies-literature
| S-EPMC7147799 | biostudies-literature